

## Paediatric inflammatory multisystem syndrome

Ramcharan, Tristan; Nolan, Oscar; Lai, Chui Yi; Prabhu, Nanda; Krishnamurthy, Raghu; Richter, Alex G; Jyothish, Deepthi; Kanthimathinathan, Hari Krishnan; Welch, Steven B; Hackett, Scott; Al-Abadi, Eslam; Scholefield, Barnaby R; Chikermane, Ashish

DOI:

[10.1007/s00246-020-02391-2](https://doi.org/10.1007/s00246-020-02391-2)

License:

None: All rights reserved

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Ramcharan, T, Nolan, O, Lai, CY, Prabhu, N, Krishnamurthy, R, Richter, AG, Jyothish, D, Kanthimathinathan, HK, Welch, SB, Hackett, S, Al-Abadi, E, Scholefield, BR & Chikermane, A 2020, 'Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a uk tertiary paediatric hospital', *Pediatric Cardiology*, vol. 41, no. 7, pp. 1391–1401. <https://doi.org/10.1007/s00246-020-02391-2>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

This is a post-peer-review, pre-copyedit version of an article published in *Pediatric Cardiology*. The final authenticated version is available online at: <https://doi.org/10.1007/s00246-020-02391-2>

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# Pediatric Cardiology

## Paediatric Inflammatory Multisystem Syndrome – Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-term Outcomes at a UK Tertiary Paediatric Hospital --Manuscript Draft--

<b>Manuscript Number:</b>	PEDC-D-20-00443
<b>Full Title:</b>	Paediatric Inflammatory Multisystem Syndrome – Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-term Outcomes at a UK Tertiary Paediatric Hospital
<b>Article Type:</b>	Original Article
<b>Corresponding Author:</b>	Ashish Chikermane, MRCPCH Birmingham Women's and Children's NHS Foundation Trust Birmingham, West Midlands UNITED KINGDOM
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	Birmingham Women's and Children's NHS Foundation Trust
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Tristan Ramcharan, MRCPCH
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Tristan Ramcharan, MRCPCH Oscar Nolan, MRCPCH Chui Yi Lai, MBBS Nanda Prabhu, MD Raghu Krishnamurthy, FRCPCH Alex G. Richter, FRCPATH PhD Deepthi Jyotish, FRCPCH Hari Krishnan Kanthimathinathan, MD Steven B. Welch, MSc FRCPCH Scott Hackett, FRCPCH MD Eslam Al-Abadi, MRCPCH Barnaby R Scholefield, MRCPCH PhD Ashish Chikermane, MRCPCH
<b>Order of Authors Secondary Information:</b>	
<b>Funding Information:</b>	
<b>Abstract:</b>	<p>Background: Children were relatively spared during COVID-19 pandemic. However, the recently reported hyperinflammatory syndrome with overlapping features of Kawasaki disease and toxic shock syndrome - "Paediatric Inflammatory Multisystem Syndrome-temporally associated with SARS-CoV-2" (PIMS-TS) has caused concern. We describe cardiac findings and short-term outcomes in children with PIMS-TS at a tertiary children's hospital.</p> <p>Methods: Single-centre observational study of children with PIMS-TS from 10<sup>th</sup> April to 9<sup>th</sup> May 2020. Data on ECG and echocardiogram were retrospectively analysed along with demographics, clinical features and blood parameters.</p>

Results: Fifteen children with median age of 8.8 (IQR 6.4-11.2) years were included, all were from African/Afro-Caribbean, South Asian, Mixed or other minority ethnic groups. All showed raised inflammatory/cardiac markers (CRP, ferritin, Troponin I, CK and pro-BNP). Transient valve regurgitation was present in 10 patients (67%). Left Ventricular ejection fraction was reduced in 12 (80%), fractional shortening in 8 (53%) with resolution in all but 2. Fourteen (93%) had coronary artery abnormalities, with normalisation in 6. ECG abnormalities were present in 9 (60%) which normalised in 6 by discharge. Ten (67%) needed inotropes and/or vasopressors. None needed extracorporeal life support. Improvement in cardiac biochemical markers was closely followed by improvement in ECG/echocardiogram. All patients were discharged alive and twelve (80%) have been reviewed since.

Conclusions: Our entire cohort with PIMS-TS had cardiac involvement and this degree of involvement is significantly more than other published series and emphasises the need for specialist cardiac review. We believe that our multi-disciplinary team approach was crucial for the good short-term outcomes.

**Paediatric Inflammatory Multisystem Syndrome – Temporally Associated with SARS-CoV-2  
(PIMS-TS): Cardiac Features, Management and Short-term Outcomes at a UK Tertiary  
Paediatric Hospital**

Authors: Tristan Ramcharan MRCPCH<sup>1</sup>, Oscar Nolan MRCPCH<sup>1</sup>, Chui Yi Lai MBBS<sup>1</sup>, Nanda Prabhu MD<sup>1</sup>, Raghu Krishnamurthy FRCPCH<sup>2</sup>, Alex G. Richter FRCPATH PhD<sup>3</sup>, Deepthi Jyothish MRCPCH<sup>4</sup>, Hari Krishnan Kanthimathinathan MD<sup>5,6</sup>, Steven B Welch MSc FRCPCH<sup>7</sup>, Scott Hackett FRCPCH MD<sup>7</sup>, Eslam Al-Abadi MRCPCH<sup>6,8</sup>, Barnaby R Scholefield MRCPCH PhD<sup>5,9\*</sup>, Ashish Chikermane MRCPCH<sup>1\*</sup>

<sup>1</sup>Department of Cardiology, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, B4 6NH, United Kingdom

<sup>2</sup>Department of Paediatrics, Manor Hospital, Walsall, WS2 9PS, United Kingdom

<sup>3</sup>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.

<sup>4</sup>Department of Paediatrics, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, B4 6NH, United Kingdom.

<sup>5</sup>Paediatric Intensive Care Unit, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, B4 6NH, United Kingdom

<sup>6</sup>Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT, UK.

<sup>7</sup>Department of Paediatrics, Birmingham Chest Clinic and Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B9 5SS, UK.

<sup>8</sup>Childhood Arthritis and Rheumatic Diseases Unit, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, B4 6NH, United Kingdom

<sup>9</sup>Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, B15 2TT, UK.

\*Joint senior authors

Address for Correspondence:

Dr Ashish Chikermane MRCPCH

Department of Cardiology, Birmingham Women and Children's NHS Foundation Trust,

Steelhouse Lane, Birmingham, United Kingdom, B4 6NH.

Tel: +441213339999

Mail: [a.chikermane@nhs.net](mailto:a.chikermane@nhs.net)

**Abstract:**

**Background:** Children were relatively spared during COVID-19 pandemic. However, the recently reported hyperinflammatory syndrome with overlapping features of Kawasaki disease and toxic shock syndrome - “Paediatric Inflammatory Multisystem Syndrome-temporally associated with SARS-CoV-2” (PIMS-TS) has caused concern. We describe cardiac findings and short-term outcomes in children with PIMS-TS at a tertiary children’s hospital.

**Methods:** Single-centre observational study of children with PIMS-TS from 10<sup>th</sup> April to 9<sup>th</sup> May 2020. Data on ECG and echocardiogram were retrospectively analysed along with demographics, clinical features and blood parameters.

**Results:** Fifteen children with median age of 8.8 (IQR 6.4-11.2) years were included, all were from African/Afro-Caribbean, South Asian, Mixed or other minority ethnic groups. All showed raised inflammatory/cardiac markers (CRP, ferritin, Troponin I, CK and pro-BNP). Transient valve regurgitation was present in 10 patients (67%). Left Ventricular ejection fraction was reduced in 12 (80%), fractional shortening in 8 (53%) with resolution in all but 2. Fourteen (93%) had coronary artery abnormalities, with normalisation in 6. ECG abnormalities were present in 9 (60%) which normalised in 6 by discharge. Ten (67%) needed inotropes and/or vasopressors. None needed extracorporeal life support. Improvement in cardiac biochemical markers was closely followed by improvement in ECG/echocardiogram. All patients were discharged alive and twelve (80%) have been reviewed since.

**Conclusions:** Our entire cohort with PIMS-TS had cardiac involvement and this degree of involvement is significantly more than other published series and emphasises the need for specialist cardiac review. We believe that our multi-disciplinary team approach was crucial for the good short-term outcomes.

**Keywords:**

1  
2 Hyper-inflammatory  
3  
4 Kawasaki  
5  
6  
7 PIMS-TS  
8  
9 MIS-C  
10  
11 COVID-19  
12  
13 SARS-CoV-2  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Declarations

**Funding:** The authors and contributors received no funding during production of this manuscript.

**Conflicts of Interest:** There are no disclosures or conflicts of interest.

**Ethics approval:** The study was classified and registered as service evaluation following assessment using the UK NHS research governance assessment tool (<http://www.hra-decisiontools.org.uk/research/>). The study was then reviewed by the Research Governance department at our institution (Birmingham Women's and Children's NHS Foundation Trust) and deemed to not require ethical approval (R&D Director's letter of approval available).

**Consent:** All patients and/or their parents/legal guardians provided signed informed consent to inclusion of de-identified data in this report.

**Acknowledgments:** We would like to acknowledge the cardiac team at Birmingham Children's Hospital for their support in managing and investigating these patients. We would also like to thank the general paediatric, rheumatology, intensive care, retrieval teams, pharmacy and clinical management teams at Birmingham Children's Hospital for their support both with managing these patients as well as developing the MDT. We also want to acknowledge the support of the Clinical Immunology Service at the University of Birmingham.



**Introduction:**

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease (COVID-19), has rapidly spread worldwide. As of 28<sup>th</sup> May 2020, there have been an estimated 269,127 confirmed cases reported in the UK with over 37,837 deaths.<sup>1</sup> London and the West Midlands have been the epicentres in the UK.

To date, there have been very few cases of children being seriously affected by SARS-Cov-2 respiratory illness.<sup>2,3</sup> However, particularly in Europe and parts of North America, children have been presenting with a systemic inflammatory response, sharing features with other paediatric inflammatory conditions including Kawasaki disease (KD), toxic shock syndrome (TSS), bacterial sepsis and macrophage activation syndrome (MAS). Initial reports suggest many have myocardial dysfunction<sup>4</sup> and coronary artery involvement<sup>5</sup> in addition to gastrointestinal and systemic symptoms.<sup>6,7,8</sup>

This experience has been mirrored in the UK, prompting an alert and guideline from the Royal College of Paediatrics and Child Health (RCPCH)<sup>9</sup> for “Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS)” with a case definition (Table 1). The Centers for Disease Control and Prevention (CDC) have also issued an alert on this condition, under the label “Multisystem Inflammatory Syndrome in Children (MIS-C).<sup>10</sup> In response, we created a paediatric multi-disciplinary team (MDT) including cardiologists, general paediatricians, rheumatologists, infectious disease specialists, immunologists, paediatric intensivists, retrieval team, and pharmacists. We also developed a West Midlands regional management guideline to serve a population of over 1 million children.<sup>11</sup>

This article describes the cardiac manifestations, management and early outcomes for children admitted to Birmingham Children’s Hospital (BCH) with PIMS-TS.

## Methods:

1  
2 We performed a single-centre retrospective study of all patients referred for cardiovascular evaluation  
3  
4 as confirmed PIMS-TS between 10<sup>th</sup> April 2020 and 9<sup>th</sup> May 2020. Children presenting with persistent  
5  
6 fever, features of clinical and biochemical inflammation, single or multi-organ dysfunction, and/or  
7  
8 fulfilling the full or partial criteria for KD were reviewed for possible PIMS-TS at the daily MDT meeting.  
9  
10  
11 Diagnostic criteria for PIMS-TS were based on the RCPCH case definition<sup>13</sup> (Table 1).  
12  
13  
14  
15  
16

17 The study was classified and registered as service evaluation following assessment using the UK NHS  
18  
19 research governance assessment tool (<http://www.hra-decisiontools.org.uk/research/>). The study  
20  
21 was then reviewed by the Research Governance department at our institution (Birmingham Women's  
22  
23 and Children's NHS Foundation Trust) and deemed to not require ethical approval (R&D Director's  
24  
25 letter of approval available). All patients and/or their parents/legal guardians provided signed  
26  
27 informed consent to inclusion of de-identified data in this report.  
28  
29  
30  
31  
32

33  
34 Description of ethnicity was in accordance with the UK Government classification.<sup>12</sup> Investigations  
35  
36 were based on an amalgamation of RCPCH guidelines and MDT recommendations (Table 2). All  
37  
38 patients had nose and throat swab viral PCR (polymerase chain reaction) for SARS-CoV-2. Patients had  
39  
40 immunological testing for Immunoglobulin M (IgM), Immunoglobulin A (IgA) and Immunoglobulin G  
41  
42 (IgG) to viral spike glycoprotein using an Enzyme-Linked Immunosorbent Assay (ELISA) test. Blood,  
43  
44 urine and cerebrospinal fluid cultures, viral serology, and PCR panel of respiratory pathogens were  
45  
46 used to detect/exclude other causes. Chest radiographs, abdominal ultrasound and other  
47  
48 investigations were performed as clinically indicated. Patients had daily 12 lead Electrocardiogram  
49  
50  
51 (ECG) and echocardiogram initially, then as required following clinical stability.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 ECGs were reported contemporaneously and re-analysed by a single author (ON). All echocardiograms  
2 were performed on Vivid S70 GE system, and analysed using EchoPac software. Using American  
3 Society of Echocardiography guidelines<sup>16</sup> data was analysed immediately by the operator, and re-  
4 analysed independently by one author (TR). Any discrepancies between the initial reports and re-  
5 analysis of ECGs and echocardiograms were reviewed by the senior author (AC).  
6  
7  
8  
9

10  
11  
12  
13  
14 Global left ventricular (LV) systolic function was assessed with linear and 2D methods.<sup>16</sup>  
15

- 16 • Fractional shortening (FS) was based on M-mode (Motion-Mode) and categorised as either  
17 normal (25-43%), or mild (20-24%), moderate (15-19%) or severe reduction ( $\leq 14\%$ ).<sup>16</sup>  
18
- 19 • Left ventricular ejection fraction (LVEF) was based on modified Simpson's method and  
20 categorised as either normal ( $\geq 55\%$ ), or mild (45-54%), moderate (30-44%) or severe  
21 impairment ( $< 30\%$ ).<sup>16</sup>  
22
- 23 • Where mitral regurgitation was present, change of pressure over time (dp/dt) was used, and  
24 categorised into either normal ( $> 1200$  mmHg/s), or mild (901-1200 mmHg/s), moderate (600-  
25 900 mmHg/s) or severe impairment ( $< 600$  mmHg/s).  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 We accepted LVEF and a subjective assessment of the global LV function as more reliable than FS in  
39 case of discrepancy, keeping with institutional practice of using FS as a screening tool only for systolic  
40 function assessment.  
41  
42  
43  
44  
45  
46

47 Mitral annular plane systolic excursion (MAPSE), tricuspid annular plane systolic excursion (TAPSE) and  
48 z-scores were used to assess ventricular longitudinal function.<sup>17,18</sup> LV diastolic function was assessed  
49 using mitral inflow ratio (E/A), and mitral annular tissue doppler (E/E').<sup>21</sup> Coronary artery  
50 measurements were from inner edge to inner edge, and z-scores calculated.<sup>19</sup> Aneurysms were  
51 described as saccular or fusiform and classified as small ( $< 5$  mm), moderate (5-8 mm) or large ( $> 8$   
52 mm).<sup>14</sup> Dilated coronary arteries without segmental aneurysm were defined as ectatic.<sup>14</sup>  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2 CT angiogram of abdomen, thorax and head & neck was planned for the second week of illness in  
3  
4 those patients (1) with coronary aneurysms, (2) who did not respond to first line therapy, or (3) with  
5  
6 suboptimal clinical/biochemical resolution following first line therapy. Any patients with abnormal  
7  
8 coronary arteries are planned for coronary CT during follow-up. Cardiac MRI has been reserved for  
9  
10 surveillance protocol.  
11  
12  
13  
14  
15

16 **Treatment:**

17  
18 Patients had immunomodulatory treatment after a case-by-case MDT discussion, and supportive  
19  
20 treatment as per hospital standards of care. If indicated following MDT discussion, children were given  
21  
22 intravenous immunoglobulins (IVIG) at a dose of 2g/kg and high-dose aspirin at a dose of 12.5mg/kg  
23  
24 four times a day (QID). In response to this first line therapy, patients with persistent fever and/or  
25  
26 worsening inflammatory markers after 36 hours received a second dose of IVIG, and/or a three-day  
27  
28 course of intravenous (IV) methylprednisolone, followed by a weaning course of oral prednisolone.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Systemic hypotension was treated with intravenous fluid boluses as first-line therapy and with norepinephrine and vasopressin as second line. Intravenous hydrocortisone was used for refractory hypotension. Epinephrine was used for LV dysfunction (based on FS & LVEF). Thromboprophylaxis with antiplatelet therapy and anticoagulation was based on standard criteria<sup>15</sup> and hospital protocols.

Data analysis was performed using Microsoft Excel (Microsoft Corporation, Redmond, USA). Continuous data is presented as median (Inter-quartile range (IQR)) and categorical data as numbers and percentages. Where serial data was available, median (IQR) of the highest or lowest result per patient is presented as median peak or nadir result.

## **Results**

### ***Demographics and clinical presentation***

During this 1-month study period, 15 patients met the case definition for PIMS-TS (Table 3). The median age was of 8.8 years (IQR 6.4-11.2 years). Notably 14 (93%) were over 5 years of age. Eleven out of 15 (73%) were male. All patients were from African/Afro-Caribbean, South Asian, Mixed or other minority ethnic groups (Table 3).

All 15 patients presented with pyrexia (median duration of 5 days). Thirteen (87%) had gastrointestinal symptoms and 8 (53%) had features of Kawasaki disease not fulfilling diagnostic criteria. Generalised myalgia and lethargy were also reported in 4 patients each (27%).

Two patients described typical COVID-19 symptoms in the previous two months, both of whom had positive SARS-CoV-2 PCR. Another 3 patients had family members with COVID-19 symptoms in the preceding 2 months.

### ***Investigations***

Blood results (Table 3) showed raised inflammatory markers (C-reactive protein, ESR, ferritin) during the early part of the disease in keeping with published studies.<sup>5, 20</sup> Median peak C-reactive protein (CRP) was 154 (IQR 42-265)mg/L, median ESR was 75 (IQR 45-90)mm/hr, and median peak ferritin 558 (IQR 31-2891)ng/ml. Cardiac markers were elevated in all patients with median peak Troponin I 396 (IQR 100-1280)ng/L, Creatine Kinase (CK) median peak 385 (IQR 117-1615)U/L and pro-B-type Natriuretic Peptide (pro-BNP) median peak 24470 (IQR 17212-26655)pg/ml. The median peak for all three cardiac markers was on day 2 of hospital admission with gradual improvement thereafter.

1 Two patients had positive SARS-CoV-2 PCR, one at the time of admission and one four weeks  
2 previously. SARS-CoV-2 serology was available for 12 of 15 patients, all of whom were positive for the  
3 combined IgG, IgA and IgM ELISA.  
4  
5  
6  
7  
8  
9

10 Fourteen patients had chest radiographs; 7 were normal, 7 had abnormalities including pleural  
11 effusions (5), consolidation (3), cardiomegaly (2). Six patients had abdominal ultrasound due to  
12 persistent gastrointestinal symptoms, showing no abnormalities.  
13  
14  
15  
16  
17  
18

19 During their admission, two patients had non-coronary CT Angiograms and one had a MRI whole body,  
20 due to persisting inflammation despite treatment, all of which showed no evidence of vasculitis.  
21  
22  
23  
24  
25

### 26 ***Cardiac investigations***

27  
28  
29 Nine patients (60%) had abnormalities on ECG (Table 4). Six of these had normalisation of their ECG  
30 prior to discharge at median 5 days.  
31  
32  
33  
34  
35

### 36 ***Coronary Arteries***

37  
38 Fourteen patients (93%) had coronary artery abnormalities noted on echocardiography, which we  
39 have described as prominent, dilated or aneurysmal (Table 5). Of these:  
40  
41  
42

- 43 - 1 had moderate fusiform aneurysm of right coronary artery (RCA) and small fusiform  
44 aneurysm of left anterior descending artery (LAD)  
45  
46
- 47 - 6 had ectatic dilated coronaries with increased z scores of either left main coronary artery (2  
48 patients) or left anterior descending artery (4 patients).  
49  
50
- 51 - 7 had prominent coronary arteries on echocardiogram but normal measurements.  
52  
53  
54  
55

56 Of the 14 patients with coronary changes, 13 (93%) had changes at presentation whilst 1 (7%)  
57 developed abnormal appearance on day 5 of admission. In 6 (43%) the coronary appearance  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

normalized at a median 3 days, whilst the other 8 continued to have abnormal appearances at discharge.

#### *Atrioventricular valve regurgitation (AVVR) (Table 6)*

Thirteen patients had AVVR during admission, of which 10 had mitral regurgitation. There was serial improvement in 7 of these 10 patients, at median 2 days. Nine had non-physiological tricuspid regurgitation (mild-moderate), 5 of which improved at median 1 day after treatment. At discharge 7 patients had residual non-physiological AVVR. No patients had valve stenosis.

#### *Ventricular function (Tables 7 & 8)*

Fractional Shortening was reduced in 8 patients, of whom 7 had changes on presentation and 1 developed subsequent changes. For those with impaired function, median FS at its nadir was 18% (IQR 17-20%) and all normalized before discharge (median 3 days).

LV ejection fraction was impaired in 12 patients (80%), 9 at presentation and in 3, there was a reduction after admission. For those with impaired function, the median of the lowest LVEF was 44% (IQR 38-50%). One patient had severe impairment on presentation (LVEF 28%) with improvement to mild impairment (LVEF 53%) at discharge. Three had moderate impairment which all normalized by discharge. The remaining 8 patients had mild impairment, of whom 7 had normalization of LVEF at discharge and 1 had an EF of 50%. Overall, normalization of LVEF took median 4 days in these 10 patients.

MAPSE z-score was reduced in 11 patients, of whom 10 had normalization after a median of 5 days.

MR dP/dt was available on admission echocardiograms in 7 patients, in whom 4 had impairment (2 mild, 2 moderate). In the 2 patients with mild impairment, mitral regurgitation resolved after the initial

1 echocardiogram and so repeat assessment of dP/dt was not possible. For the other 2 patients with  
2 moderate impairment, MR was still present and they had normalized dP/dt at median 4 days.  
3  
4

5  
6  
7 In the 12 patients with LV dysfunction by ejection fraction, 9 also had reduced MAPSE on z-score, 8  
8 had reduced fractional shortening, and 4 reduced MR dP/dt. Of these 12 with impaired LVEF, 10  
9 normalized prior to discharge and the remaining 2 had mild impairment (LVEF 50% and 53%) at  
10 discharge.  
11  
12  
13  
14  
15

16  
17  
18  
19 Two patients had evidence of diastolic dysfunction with abnormal E/A and E/E' ratios.  
20  
21  
22

23  
24 RV systolic function was assessed using tricuspid annular excursion (TAPSE). Using z-scores of TAPSE,  
25 10 patients had impaired RV function with normalization in all at median 3 days. Subjective  
26 assessment of RV size and function did not show any abnormalities at any point.  
27  
28  
29  
30

### 31 32 33 *Effusions*

34 Small pericardial effusion was present in 8 patients, half had complete resolution by discharge at  
35 median 5 days. The remaining 4 had small pericardial effusion at discharge.  
36  
37  
38  
39  
40  
41  
42

### 43 **Management**

44 Ten patients received intravenous immunoglobulin (IVIG), of whom 2 received a second dose. Five  
45 patients received IV methylprednisolone followed by weaning course of oral prednisolone. No  
46 patients needed Infliximab. None needed therapeutic anti-coagulation. Eleven patients (73%) were  
47 discharged on low dose aspirin with 2 requiring high doses initially. All patients were treated with  
48 broad-spectrum antibiotics for at least 5 days. Ten (67%) needed intensive care with a median stay of  
49 4 days (IQR 3-5 days). Eight needed respiratory support, of whom half required mechanical ventilation  
50 (median 3 days) and others required high-flow nasal cannula support.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2 *Cardio-vascular support*  
3

4 Ten patients (67%) needed fluid resuscitation with a median of 58ml/kg (IQR 35-60ml/kg) intravenous  
5 fluid boluses given. Ten (67%) required inotropes/vasopressors for a median of 3 days (IQR 2-3 days).  
6  
7 Norepinephrine was used in 8 with additional support using vasopressin in 3 to treat systemic  
8 hypotension. Intravenous hydrocortisone was used for refractory hypotension in 8 patients. Nine  
9 required epinephrine to support LV dysfunction. One patient was transferred from an external  
10 hospital on milrinone, which was weaned off.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 No patients needed extracorporeal life support (ECLS) in our cohort.  
22  
23  
24  
25

26 **Short-term outcomes**  
27

28 There were no deaths in our cohort. Median inpatient stay was 12 days (IQR 9-13 days). All 15 patients  
29 were discharged home clinically well with normal/improving biochemical and cardiac parameters. All  
30 are planned for clinical review one week after discharge in a multi-disciplinary clinic with repeat blood  
31 tests, ECG & echocardiogram.  
32  
33  
34  
35  
36  
37  
38  
39

40 Twelve patients (80%) have had their first clinic review with stable clinical and echocardiogram  
41 findings. There were no new coronary changes and no deterioration in cardiac function. Two patients  
42 have had outpatient CT coronary angiogram, both of which have mirrored echocardiographic findings  
43 with no new abnormalities.  
44  
45  
46  
47  
48  
49  
50  
51

52 **Discussion**  
53  
54

55 The focus of this descriptive study of PIMS-TS patients from a single cardiac centre is on cardiac  
56 involvement with short-term outcomes. Although our patients shared some overlapping features with  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Kawasaki disease, we have identified some distinct features in our cohort suggesting a different  
2 pathological process as described below.  
3

4  
5  
6  
7 The median age of children in our cohort was 8.8 years, with none in the neonatal age group. In our  
8 cohort patients were older when compared to acute COVID-19 infection, where severe illness was  
9 seen more commonly in younger children.<sup>2</sup> In addition, the median age of our cohort is above the  
10 median age of children affected with Kawasaki disease in UK (< 5 years).<sup>22</sup>  
11  
12  
13  
14  
15  
16

17  
18 All children were from African/Afro-Caribbean, South Asian, Mixed or other minority ethnic groups,  
19 which is disproportional to the ethnic demographics of children in the West Midlands (3.3% Black,  
20 10% Asian).<sup>23, 24</sup> This mirrors evidence that people from such communities are at increased risk of not  
21 only acquiring COVID-19 infection, but also having worse outcomes.<sup>25, 26</sup>  
22  
23  
24  
25  
26  
27  
28  
29

30 **Paediatric intensive care (PIC) support:** Ten patients (67%) needed intensive care treatment and  
31 monitoring, mainly for their cardiovascular instability, with 8 of these patients also requiring  
32 respiratory support. This need for intensive care support is comparable to the other hitherto published  
33 studies, with 50% of patients in the Bergamo series<sup>20</sup> and 70% of the patients in the Paris study (pre-  
34 print)<sup>26</sup> needing intensive care admission.  
35  
36  
37  
38  
39  
40  
41  
42  
43

#### 44 ***Cardiac manifestations***

45  
46 All patients in our cohort had evidence of cardiac involvement based on biochemical, ECG and  
47 echocardiogram data (Table 4-8). This is significantly higher compared to the Bergamo series<sup>20</sup> where  
48 60% had cardiac involvement in the form of echocardiogram abnormalities, and the Paris series (pre-  
49 print)<sup>26</sup> where myocarditis was described in 70% of patients.  
50  
51  
52  
53  
54  
55  
56  
57  
58

#### 59 ***Biochemical markers***

60  
61  
62  
63  
64  
65

1 Cardiac biochemistry markers peaked at median day 2 of admission, with gradual improvement. This  
2 preceded improvement in ECG appearances and cardiac function, which showed an improvement by  
3  
4 median days 5 and 4 respectively. We could therefore be reassured by biochemical improvement and  
5  
6 use this along with ECG/echocardiographic improvement as confirmation of clinical improvement.  
7  
8  
9

### 10 11 *Systemic hypotension*

12 This is present in only 5% of KD patients,<sup>14</sup> but common in our cohort (67% needing fluid  
13  
14 resuscitation/inotropic/vasopressor support) in keeping with the Bergamo data at 50%.<sup>20</sup>  
15  
16  
17  
18  
19  
20

### 21 *AV valve regurgitation*

22 Mitral and/or tricuspid valve regurgitation was present in 13 patients (87%), with significant  
23  
24 improvement at median 1-2 days suggesting a transient valvulitis.  
25  
26  
27  
28  
29  
30

### 31 *LV function*

32 There was global LV dysfunction in 12 patients (80%) by LVEF, with normalization occurring in 10  
33  
34 children by discharge. This is higher than that in the Bergamo cohort with 50% of patients having  
35  
36 abnormal LVEF<sup>20</sup> and is comparable to the Paris cohort (pre-print) with 71% of patients having  
37  
38 abnormal LVEF<sup>26</sup>. In addition, mild LV dysfunction was noted in 4 patients on eyeballing and LVEF  
39  
40 (Simpson's method) when the shortening fraction was normal. This highlights the need for specialist  
41  
42 and thorough cardiac evaluation of all patients with PIMS-TS.  
43  
44  
45  
46  
47  
48  
49

### 50 *Coronary arteries*

51 Although only half of our patients with abnormal coronary artery appearances had objective dilation,  
52  
53 the remaining half were subjectively reported to be "echo-bright" by at least 2 different observers.  
54  
55  
56 Notably, the coronary arteries in the older children were visualised much easier than would be  
57  
58 expected on echocardiography. This mirrors the description of the Paris group (pre-print)<sup>26</sup> with  
59  
60  
61  
62  
63  
64  
65

1 coronary involvement in 45% of cases (no aneurysms, 29% dilated), and of the Evelina (London) group  
2 with reports of “echo-bright coronary vessels”<sup>5</sup>. This may be explained by endothelial inflammation of  
3  
4 coronary arteries and warrants careful monitoring over time to identify coronary artery complications.  
5  
6  
7

### 8 9 *Management*

10  
11 The focus of management was to modulate hyperinflammation. From a cardiovascular perspective,  
12  
13 patients mainly needed vasopressor support for hypotension. One patient was started on milrinone  
14  
15 at another centre prior to transfer and this was weaned off after admission. Our institutional  
16  
17 preference is a combination of norepinephrine and vasopressin to support blood pressure.  
18  
19 Epinephrine was used to support LV dysfunction. The use of milrinone as an inotrope was avoided in  
20  
21 this cohort due to the counterproductive effect of peripheral vasodilation. All patients were  
22  
23 discharged on low dose aspirin to reduce the incidence of coronary artery events.  
24  
25  
26  
27  
28  
29

### 30 31 *Follow-up*

32  
33 All patients were clinically well at the time of discharge, and 12 have had their first follow-up review  
34  
35 with no clinical concerns. Echocardiogram and CT coronary angiograms have confirmed no new  
36  
37 findings or deterioration. These reflect the clinical improvement seen prior to discharge with good  
38  
39 short-term outcomes.  
40  
41  
42  
43

### 44 45 *Strengths & Limitations*

46  
47 This study has the limitations of representing a small case series and requires further collaboration at  
48  
49 national and international levels. The management described cannot be construed as treatment  
50  
51 recommendations. Some other patients in the region, especially with milder illness may have not been  
52  
53 referred to our hospital. Only short-term outcomes have been described. Long term follow-up is  
54  
55 planned and would be essential to define the late outcomes for this patient cohort. Strengths of the  
56  
57 study include detailed granular cardiac data in the small number of patients described and the  
58  
59  
60  
61  
62  
63  
64  
65

1 consistent multi-disciplinary team involvement, which reduced some of the variability in  
2 management. Further research is needed to understand the epidemiology, natural history, and  
3  
4 immunopathology of PIMSTS.  
5  
6  
7  
8  
9

10  
11 **Summary:**

12 We have described a detailed cardiac assessment of a cohort of patients with PIMS-TS. All the patients  
13  
14 in our cohort had impaired left ventricular function, valve regurgitation and/or coronary artery  
15  
16 involvement, with good recovery in most by the time of discharge. There was a high incidence of  
17  
18 cardio-vascular instability with systemic hypotension. Early management was targeted to reduce  
19  
20 inflammation and medium to long-term complications. However, long-term follow up will be essential  
21  
22 and cardiac vigilance is needed in paediatric and potentially adult cohorts, as this condition is  
23  
24 understood further.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Reference List

1. UK government. Coronavirus (COVID-19) in the UK. May 2020.  
(<https://coronavirus.data.gov.uk/>)
2. Dong Y, Mo X, Hu Y et al. Epidemiology of COVID-19 Among Children in China. *Pediatrics*. 2020 Mar 16:e20200702. Epub ahead of print. PMID: 32179660.
3. Docherty A, Harrison E, Green C et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020;369:m1985. Published 2020 May 22. doi:  
<https://doi.org/10.1136/bmj.m1985>
4. Bertonecchi D, Guidarini M, Della Greca A et al. COVID19: potential cardiovascular issues in pediatric patients. *Acta Biomed*. 2020;91(2):177-183. Published 2020 May 11.  
doi:10.23750/abm.v91i2.9655
5. Riphagen S, Gomez X, Gonzalez-Martinez C et al. Hyperinflammatory shock in children during COVID-19 pandemic [published online ahead of print, 2020 May 7]. *Lancet*. 2020;S0140-6736(20)31094-1. doi:10.1016/S0140-6736(20)31094-1
6. Lu X, Zhang L, Du H et al. SARS-CoV-2 Infection in Children. *N Engl J Med*. 2020;382(17):1663–1665
7. Wei M, Yuan J, Liu Y et al. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China [published online ahead of print, 2020 Feb 14]. *JAMA*. 2020;323(13):1313–1314
8. Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. *Pediatr Infect Dis J*. 2020;39(5):355–368

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
9. RCPCH Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. Royal College of Paediatrics and Child Health.  
(<https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19>)
10. Information for Paediatric Healthcare Providers <https://www.cdc.gov/coronavirus/2019-ncov/hcp/pediatric-hcp.html>)
11. Office for National Statistics. Subnational population projections for England: 2018-based.  
(<https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/bulletins/subnationalpopulationprojectionsforengland/2018based>)
12. UK Government: List of ethnic groups (<https://www.ethnicity-facts-figures.service.gov.uk/ethnic-groups>)
13. Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. Royal College of Paediatrics and Child Health.  
(<https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19>)
14. McCrindle BW, Rowley AH, Newburger JW et al. (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American heart association. *Circulation* 135, e927– 99
15. Low DE. Toxic shock syndrome: major advances in pathogenesis, but not treatment. *Crit Care Clin.* 2013 Jul;29(3):651-75. PMID: 23830657.
16. RL Lang et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2015;28:1-39
17. Koestenberger M, Ravekes W, Everett AD et al. Right ventricular function in infants, children and adolescents: reference values of the tricuspid annular plane systolic excursion (TAPSE) in

640 healthy patients and calculation of z score values. J Am Soc Echocardiogr. 2009

Jun;22(6):715-9.43

18. Koestenberger M, Nagel B, Ravekes W et al. Left ventricular long-axis function: reference values of the mitral annular plane systolic excursion in 558 healthy children and calculation of z-score values. Am Heart J. 2012 Jul;164(1):125-31. doi: 10.1016/j.ahj.2012.05.004. Epub 2012 Jun 20
19. Lopez L, Colan S, Stylianou M et al. Relationship of Echocardiographic Z Scores Adjusted for Body Surface Area to Age, Sex, Race, and Ethnicity. Circ Cardiovasc Imaging. 2017 Nov;10(11).
20. Verdoni L, Mazza A, Gervasoni A et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. Published online May 13, 2020. [https://doi.org/10.1016/S0140-6736\(20\)31103-X](https://doi.org/10.1016/S0140-6736(20)31103-X)
21. Eidem BW, McMahon CJ, Cohen RR et al. (2004) Impact of cardiac growth on Doppler tissue imaging velocities in healthy children. J Am Soc
22. Tulloh RMR, Mayon-White R, Harnden A et al. Kawasaki disease: a prospective population survey in the UK and Ireland from 2013 to 2015. Arch Dis Child. 2019 Jul;104(7):640-646. Erratum in: Arch Dis Child. 2020 Mar;105(3):e5. PMID: 30104394.
23. UK Government: Regional ethnic diversity (<https://www.ethnicity-facts-figures.service.gov.uk/uk-population-by-ethnicity/national-and-regional-populations/regional-ethnic-diversity/latest>)
24. Birmingham City Council: 2011 ethnic group by age ward. ([https://www.birmingham.gov.uk/downloads/file/9839/2011\\_ethnic\\_group\\_by\\_age\\_ward](https://www.birmingham.gov.uk/downloads/file/9839/2011_ethnic_group_by_age_ward))
25. Pareek M, Bangash MN, Pareek N et al. Ethnicity and COVID-19: an urgent public health research priority. Lancet. 2020 May 2;395(10234):1421-1422. Epub 2020 Apr 21. PMID: 32330427; PMCID: PMC7173801.



26. Julie Toubiana, Clement Poirault, Alice Corsia et al. Outbreak of Kawasaki disease in children  
during COVID-19 pandemic: a prospective observational study in Paris, France  
medRxiv 2020.05.10.20097394; doi:<https://doi.org/10.1101/2020.05.10.20097394>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Table 1: RCPCH case definition for PIMS-TS, including Clinical features and abnormalities seen on recommended investigations <sup>5</sup>

<b>RCPCH Case Definition:</b>		
<p>1. A child presenting with persistent fever, inflammation (neutrophilia, elevated CRP and lymphopenia) and evidence of single or multi-organ dysfunction (shock, cardiac, respiratory, renal, gastrointestinal or neurological disorder) with additional features (see below). This may include children fulfilling full or partial criteria for Kawasaki disease.</p> <p>2. Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with myocarditis such as enterovirus (waiting for results of these investigations should not delay seeking expert advice).</p> <p>3. SARS-CoV-2 PCR testing may be positive or negative</p>		
<b>Imaging and ECG:</b>	<b>Clinical:</b>	<b>Laboratory:</b>
<ul style="list-style-type: none"> <li>• Echocardiogram &amp; ECG – myocarditis, valvulitis, pericardial effusion, coronary artery dilatation</li> <li>• CXR – patchy symmetrical infiltrates, pleural effusion</li> <li>• Abdo USS – colitis, ileitis, lymphadenopathy, ascites, hepatosplenomegaly</li> </ul>	<p>All:</p> <ul style="list-style-type: none"> <li>• Persistent fever &gt;38.5°C</li> </ul> <p>Most:</p> <ul style="list-style-type: none"> <li>• Oxygen requirement</li> <li>• Hypotension</li> </ul> <p>Some:</p> <ul style="list-style-type: none"> <li>• Abdominal pain</li> <li>• Confusion</li> <li>• Conjunctivitis</li> <li>• Cough</li> <li>• Diarrhoea</li> </ul>	<p>All:</p> <ul style="list-style-type: none"> <li>• Abnormal Fibrinogen</li> <li>• Absence of potential causative organisms (other than SARS-CoV-2)</li> <li>• High CRP</li> <li>• High D-Dimers</li> <li>• High ferritin</li> <li>• Hypoalbuminemia</li> <li>• Lymphopenia</li> <li>• Neutrophilia in most – normal neutrophils in some</li> </ul> <p>Some:</p>

<p>1</p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p> <p>26</p> <p>27</p> <p>28</p> <p>29</p> <p>30</p> <p>31</p> <p>32</p> <p>33</p> <p>34</p> <p>35</p> <p>36</p> <p>37</p> <p>38</p> <p>39</p> <p>40</p> <p>41</p> <p>42</p> <p>43</p> <p>44</p> <p>45</p> <p>46</p> <p>47</p> <p>48</p> <p>49</p> <p>50</p> <p>51</p> <p>52</p> <p>53</p> <p>54</p> <p>55</p> <p>56</p> <p>57</p> <p>58</p> <p>59</p> <p>60</p> <p>61</p> <p>62</p> <p>63</p> <p>64</p> <p>65</p>	<ul style="list-style-type: none"> <li>• CT chest – patchy symmetrical infiltrates, pleural effusion, may demonstrate coronary artery abnormalities if with contrast</li> </ul>	<ul style="list-style-type: none"> <li>• Headache</li> <li>• Lymphadenopathy</li> <li>• Mucus membrane changes</li> <li>• Neck swelling</li> <li>• Rash</li> <li>• Respiratory symptoms</li> <li>• Sore throat</li> <li>• Swollen hands and feet</li> <li>• Syncope</li> <li>• Vomiting</li> </ul>	<ul style="list-style-type: none"> <li>• Acute kidney injury</li> <li>• Anaemia</li> <li>• Coagulopathy</li> <li>• High IL-10</li> <li>• High IL-6</li> <li>• Neutrophilia</li> <li>• Proteinuria</li> <li>• Raised CK</li> <li>• Raised LDH</li> <li>• Raised triglycerides</li> <li>• Raised troponin</li> <li>• Thrombocytopenia</li> <li>• Transaminitis</li> </ul> <p>*These assays are not widely available. CRP can be used as a surrogate marker for IL-6</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RCPCH indicates Royal College of Paediatrics and Child Health; PIMS-TS, paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; CRP, C-reactive protein; PCR, polymerase chain reaction; ECG, electrocardiogram; CXR, chest x-ray; USS, ultrasound scan; CT, computerised tomography; IL, interleukin; CK, creatinine kinase; LDH, lactate dehydrogenase

Table 2: Investigations as part of PIMS-TS screen

<p><b>Blood Tests:</b></p> <ul style="list-style-type: none"> <li>• FBC and Film</li> <li>• U+E</li> <li>• LFT</li> <li>• CRP</li> <li>• ESR</li> <li>• Glucose</li> <li>• Blood gas with lactate</li> <li>• Coagulation + Fibrinogen</li> <li>• D-Dimer</li> <li>• LDH</li> <li>• Triglycerides</li> <li>• Ferritin</li> <li>• Troponin I</li> <li>• Pro-BNP</li> <li>• CK</li> <li>• Vitamin D</li> <li>• Amylase</li> <li>• Save EDTA and serum for PCR and serological studies (pre IVIG)</li> </ul>	<p><b>Microbiology:</b></p> <ul style="list-style-type: none"> <li>• Blood culture</li> <li>• Urine and stool culture</li> <li>• Throat swab culture</li> <li>• NPA or throat swab for respiratory panel</li> <li>• Mycoplasma titres</li> <li>• Pneumococcal, Meningococcal, Group A strep, Staph aureus Blood PCR</li> <li>• Anti-Streptolysin O Titre</li> <li>• EBV, CMV, Adenovirus, Parvovirus, Enterovirus PCR on Blood</li> <li>• HIV</li> <li>• Blood for enterotoxin/staph toxins</li> <li>• Stool for virology</li> </ul>
<p><b>Cardiac investigations:</b></p> <ul style="list-style-type: none"> <li>• ECG</li> <li>• Echocardiogram</li> </ul>	<p><b>SARS-CoV-2 Investigations:</b></p> <ul style="list-style-type: none"> <li>• SARS-CoV-2 Respiratory PCR</li> <li>• Consider PCR on stool and blood</li> <li>• SARS-CoV-2 serology</li> </ul>

PIMS-TS indicates paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; FBC, full blood count; U+E, urea and electrolytes; LFT, liver function test; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; BNP, B type natriuretic peptide; CK, creatinine kinase; EDTA, ethylenediaminetetraacetic acid; PCR, polymerase chain reaction; IVIG, intravenous immunoglobulin; ECG, electrocardiogram; NPA, nasopharyngeal aspirate; EBV, Epstein-Barr virus; CMV, cytomegalovirus; HIV, human immunodeficiency virus

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Table 3: Overview of patient cohort

<b>Total patients (n=15)</b>	
Median Age (IQR) years	8.8 (6.4-11.2)
Gender (Male: Female)	2.75:1
Median Weight (IQR) kg	34.7 (24.2-40.2)
Median Height (IQR) cm	137.6 (128.9-146.5)
<b>Ethnicity in number (percentage)</b>	
African/Afro-Caribbean	6 (40%)
South Asian	6 (40%)
Mixed	2 (13%)
Other	1 (7%)
<b>PICU support in number (percentage)</b>	
Respiratory support*	8 (53%)
Inotrope or vasopressor†	10 (67%)
<b>Blood results Median (IQR Range):</b>	
Ferritin peak (ng/mL)	558 (364-1325)
Normal 14-79	
CRP peak (mg/L)	154 (129-231)
Normal <10	
ESR peak (mm/hr)	75 (45-90)
Normal 0-9	
D-Dimer peak (µg/mL)	2.06 (1.16-2.61)
Normal <0.30	

Troponin I peak (ng/L) Normal <35 ng/L	396 (100-1280)
Pro-BNP peak (pg/ml) Normal <400	24470 (17212-26655)
CK peak (U/L) Normal 75-235	385 (117-1615)

PICU indicates paediatric intensive care unit; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; BNP, B- type natriuretic peptide; CK, creatinine kinase.

\*included invasive mechanical ventilation or humidified high flow nasal prong oxygen

†included epinephrine, norepinephrine or vasopressin

Table 4: ECG changes in individual patients

	At admission:					At discharge:
	Rhythm	PR Interval	QRS Interval	T waves	ST	
1	N	N	N	A	N	A
2	N	N	N	A	N	N
3	N	N	N	A	N	N
4	N	N	N	A	N	N
5	N	N	N	A	N	N
6	N	N	N	A	N	N
7	N	N	N	N	N	N
8	N	N	N	N	N	N
9	N	A	N	N	N	A
10	N	N	N	N	N	N
11	N	A	N	A	N	A
12	N	N	N	N	N	N
13	N	N	N	N	N	N
14	N	N	N	N	N	N
15	N	N	N	A	N	N

ECG indicates electrocardiogram; N, normal; A, abnormal



Table 5: Coronary artery changes seen in individual patients

	At admission:	Most abnormal:	At discharge:
1	N	N	N
2	D	D	N
3	P	P	N
4	P	P	P
5	P	P	N
6	D	D	D
7	A	A	A
8	D	D	D
9	D	D	N
10	P	P	P
11	P	P	P
12	P	P	P
13	N	P	N
14	D	D	D
15	D	D	N

A indicates aneurysmal; D, dilated; P, prominent; N, normal

Table 6: Degree of atrioventricular valve regurgitation in individual patients

	At worst		At discharge	
	Mitral	Tricuspid	Mitral	Tricuspid
1	N	M	N	N
2	M	M	N	N
3	N	N	N	T
4	M	M	N	N
5	T	T	N	T
6	M	M	M	T
7	N	T	N	T
8	T	T	T	T
9	N	M	N	M
10	M	T	M	T
11	M	M	N	M
12	M	T	T	T
13	M	Mo	T	M
14	N	M	N	N
15	Mo	M	N	N

N indicates no regurgitation; T, trivial; M, mild; Mo, moderate

Table 7: Details of echocardiogram results of children with PIMS-TS (n=15)

	Admission result (median)	Discharge (median)	Patients with impaired function	
			Most impaired result (median)	Time to normalisation (median - days)
LV FS* (%)	29	35	18	3
LVEF† (%)	51	58	43.5	4
MR dP/dt(mmHg/s)	1140	1584	956	4
MAPSE (z-score)	-2.8	+0.6	-3.6	5
TAPSE (z-score)	-2.4	+2.7	-3.7	3

PIMS-TS indicates paediatric inflammatory multisystem syndrome-temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); LV, left ventricle; FS, fractional shortening; EF, ejection fraction; MR, mitral regurgitation; dP/dt, change of pressure over time; MAPSE, mitral annular plane systolic excursion; TAPSE, tricuspid annular plane systolic excursion

\* FS was assessed using standard M-mode in parasternal views† EF was estimated using modified Simpson's method on 2D

Table 8: Individual patient echocardiogram results when most impaired during admission and at discharge

	<b>Most impaired:</b>	FS (%)	LVEF (%)	dP/dt (mmHg/s)	MAPSE z-score	<b>At discharge:</b>	FS (%)	LVEF (%)	dP/dt (mmHg)	MAPSE z-score
1	S	16	28		-3.1	M	30	53		-1.6
2	M	20	42	863	-5.3	N	35	66	1237	-3.4
3	M	17	43		-4.1	N	31	57		1.5
4	Mo	20	32	844	-3.6	N	43	57	1586	-1.2
5	M	23	45	1246	-4.5	N	30	55		-0.8
6	M	28	50	1584	-3.3	N	35	64	1584	-1.9
7	M	32	51		2.8	N	41	58		3.6
8	M	32	50		2.8	M	35	50		1.7
9	N	29	56		-3.4	N	42	63		3
10	N	34	55	2800		N	34	55		
11	Mo	16	38	1140	-3.4	N	35	59		1.3
12	M	33	53		-3.6	N	35	55		-0.7
13	Mo	18	37		-3.1	N	30	69		4.2
14	N	34	62		-4.2	N	34	72		2.1
15	M	18	44	1048	-0.03	N	32	64		-0.03

FS indicates fractional shortening; LVEF, left ventricular ejection fraction; dP/dt, difference of pressure over time; MAPSE, mitral annular plane systolic excursion; N, normal; M, mildly impaired; Mo, moderately impaired; S, severely impaired